

San Francisco Spring Group Meeting

SPECIALS

Breast Committee

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair:Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians:Allison Meisner, PhD
 Danika Lew, MA
Shay Bellasea, MS
 Allison Hayes, BS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: TBD
 Pathology:David L. Rimm, MD, PhD
 Early Therapeutics:Stephanie L. Graff, MD

Designates

Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
Helen K. Chew, MD (Symptom Management)
 Digital Engagement: TBD
 NCORP Representative:Philip E. Lammers, MD
 Veterans Affairs:Sarah V. Colonna, MD
 Data Coordinators:Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Kevin Moralda, BS
 Larry G. Kaye
 Oncology Research Professionals:
 CRAs: Karyn N. Hart, CCRP
 Nurse: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: TBD
 Clinical Trials Program Manager:Sharon Palmer

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Seacliff BCD (Bay Level)

Agenda

4:30 - 4:35 pm Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

Educational Session

"Emerging Novel Predictors for Treatment Optimization in Breast Cancer"

4:35 - 4:50 pm AI Predictor in Early-Stage Hormone Positive Breast Cancer - George Sledge, MD, Caris Life Sciences

4:50 - 5:05 pm Optimizing Patient Selection in Clinical Trials Using a CLIA-Based RPPA Assay for Functional Protein Drug Target Activation Mapping - Chip Petricoin, PhD, George Mason University

5:05 - 5:20 pm Q&A

Committee Business and Updates

5:20 - 5:30 pm Publication update – Allison Meisner, PhD

5:30 - 5:40 pm Patient Advocate update – Ginny Mason and Roberta Albany

5:40 - 5:50 pm Translational Medicine Sub-Committee update - Alastair Thompson, MD and Andrew K. Godwin, PhD

5:50 - 6:20 pm Review of open CTSU trials

6:30 - 6:30 pm Reports from Committee Liaisons

Radiotherapy: Reshma Jagsi, MD
 Surgery: Joshua Mammen, MD
 Survivorship: Mariya Rozenblit, MD
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Symptom Management: Helen K. Chew, MD
 NCORP: Philip Lammers, MD

6:30 pm Closing Comments and Adjourn

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.

Breast Committee

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 07/21/23.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16; Permanently closed: 06/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 09/04/13; Permanently closed: 05/01/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 09/12/18. Permanently closed: 07/01/24.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3

N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 02/07/14; Permanently closed: 07/01/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 05/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15; Permanently closed: 04/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19; Permanently closed: 07/01/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17; Permanently closed: 12/02/22.

Active Palliative Care Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17. Arms 1 and 2 permanently closed to accrual: 11/01/2024.

Breast Committee

Closed Symptom Management and Survivorship Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Study

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 07/16/18.

Closed Prevention, Screening & Surveillance Studies

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 09/01/20. Permanently closed: 06/14/2024.

CTS/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17. Closed to accrual: 12/20/2024.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 01/13/17; Permanently closed: 03/15/23.

CTS/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S0307/Other Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study. El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard MF, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnant M, Clemons M, El Emam K. J Med Internet Res. Mar 5;27:e66821, 2025 <https://pubmed.ncbi.nlm.nih.gov/40053790/>

S1007 Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007). Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K. J Natl Cancer Inst Dec 5:Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/39656951/>

S1007/S8814 Development and validation of the RSclinN+ tool that integrates the 21-gene recurrence score and clinical variables to predict prognosis and chemotherapy benefit for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer. Pusztai L, Hoag J, Albain K, Barlow W, Stemmer S, Meisner A, Hortobagyi G, Shak S, Rae J, Baehner R, Sharma P, Kalinsky K. J Clin Oncol. Mar 10;43(8):919-928, 2025. <https://pubmed.ncbi.nlm.nih.gov/39621968/>

C40603 Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. Felsheim B, Fernandez Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, Somlo G, Carey L, Sikov W, Perou C. NPJ Breast Cancer Mar 8;11(1):24, 2025. <https://pubmed.ncbi.nlm.nih.gov/40057511/>

Submitted Manuscripts

None this cycle

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	EA1181	EA1183	EA1211	MA39
Banner MD Anderson Cancer Center	-	-	-	-	12	-	-	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	10	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	2	5	-	-	1	-	2	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	2	-	-	-	-	-	3
Boston Medical Center	-	-	-	-	6	-	15	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	4	-	-	2
Cancer Research Consortium of West Michigan NCORP	1	-	-	8	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	3	1	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	1	4	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	2	2	12	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	4	1	1	1	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	9	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	4	-	1	-	-	-	3	-	-	-
CommonSpirit Health Research Institute	2	-	-	7	-	-	-	-	-	2
Dayton NCI Comm Oncology Research Program	-	1	-	-	-	-	6	2	-	-
Desert Regional Medical Center	1	-	-	-	-	-	2	-	-	1
Essentia Health NCI Comm Oncology Research Program	-	-	1	-	1	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	2	-	2	3	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	3	6	-	-	2	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	4	-	3	17	1	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	2	2	5	-	-	1
Henry Ford Hospital	-	-	1	2	-	3	-	-	-	-
Houston Methodist Hospital	-	-	-	-	1	-	-	-	-	3
Lahey Hospital & Medical Center	-	-	1	2	1	-	6	-	-	-
Loma Linda University Medical Center	-	-	-	4	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	1	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	1	-	-	1	-	3	-	4
Michigan Cancer Research Consortium NCORP	2	-	2	8	-	-	-	-	-	-
Montana Cancer Consortium NCORP	3	-	-	4	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1	-	-	-
MultiCare Tacoma General Hospital	-	-	4	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	3	-	-	-	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	EA1181	EA1183	EA1211	MA39
New Mexico Minority Underserved NCORP	6	1	-	-	-	1	-	-	-	-
Northwell Health NCORP	-	1	1	-	-	-	-	-	-	-
Northwestern University LAPS	1	2	-	14	1	-	4	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	4	-	-	1	-	-	-
Oregon Health & Science University	-	-	1	-	-	-	-	3	-	-
Pacific Cancer Research Consortium NCORP	2	-	5	12	-	-	-	-	-	2
Rhode Island Hospital	-	-	-	1	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	6	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	2	26	1	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	2	3	-	5	-	-	-
The Don & Sybil Harrington Cancer Center	3	-	-	-	3	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	11	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	-	-	2	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	2	-	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	1	-	-	-	-	2
U of Alabama at Birmingham / Deep S. Research Consortium LAPS	-	2	-	5	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	1	2	3	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	1	1	1	-	11	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	4	8	1	-	-	-	-	3
University of Michigan Comprehensive Cancer Center LAPS	3	-	2	1	2	2	1	-	-	14
University of Mississippi Medical Center	-	-	-	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	2	2	-	-	-	-	1	-
University of Rochester LAPS	1	-	-	-	-	-	1	-	-	-
University of Texas Health Science Center at San Antonio	-	1	3	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	2	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	5	-	-	-	1	-	7	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	2	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	5	2	-	14	4	3	3
Western States Cancer Research NCORP	-	-	-	-	-	-	2	-	-	-
Wisconsin NCI Comm Oncology Research Program	1	-	-	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	16	3	-	13	-	-	-
ALLIANCE	18	7	14	87	-	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	11	3	15	70	-	-	-	-	-	-
NRG	48	-	7	54	-	-	-	-	-	-
Total	160	25	92	431	51	15	120	13	6	42

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR009
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
Columbia University Minority Underserved NCORP	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	-
Desert Regional Medical Center	-	-
Essentia Health NCI Community Oncology Research Program	-	-
Fred Hutchinson Cancer Research Center LAPS	-	1
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Gulf South Minority Underserved NCORP	-	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	1
Henry Ford Health Providence Southfield Hospital	-	2
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Lahey Hospital and Medical Center	-	-
Loma Linda University Medical Center	-	-
Loyola University Medical Center	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-
Michigan Cancer Research Consortium NCORP	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
MultiCare Tacoma General Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR009
New Mexico Minority Underserved NCORP	-	-
Northwell Health NCORP	2	-
Northwestern University LAPS	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	1	-
Pacific Cancer Research Consortium NCORP	-	-
Rhode Island Hospital	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-
Sutter Cancer Research Consortium	2	1
The Don and Sybil Harrington Cancer Center	-	-
The West Clinic - Wolf River	-	2
UC Davis Comprehensive Cancer Center LAPS	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	3	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-
University of Michigan Comprehensive Cancer Center LAPS	-	-
University of Mississippi Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	-	-
University of Rochester LAPS	1	-
University of Texas Health Science Center at San Antonio	4	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
CCTG	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	16	8

